Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Vantage Pharma, Biotech and Medtech 2018 in Review
Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong The Vantage 2018 in Review paints a mixed picture for biopharma and medtech in 2018. Key indicators on share price and dealmaking showed weakness, but there are signs of health from the industry in IPO outcomes, venture financing…
Report library
EvaluatePharma World Preview 2018, Outlook to 2024
Report Highlights Worldwide prescription drug sales accelerate to $1.2 trillion by 2024, as unmet need drives annual compound growth to over 6% R&D spend is…
EvaluatePharma Orphan Drug Report 2018
Report Highlights Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024 The mean price of the top 100 USA orphan drugs is expected to…
ASCO: Skirmishes Break Out In The Great Lung Cancer Battle
Report Highlights For prescribers, at least, it is becoming ever more important to stay up to date with the numerous subgroups into which first-line NSCLC is being…
EP Vantage Pharma, Biotech and Medtech 2017 In Review
Report Highlights All major healthcare indices climbed in 2017, echoing wider stock market strength The $80bn spent on pharma & biotech acquisitions in 2017 makes…
EP Vantage 2018 Preview
Report Highlights M&A activity expected to climb after slow 2017 – US tax reform a deciding factor for big deals Another big year predicted for venture financing…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.